Metformin and resveratrol activate AMPK indirectly by inhibiting the mitochondrial ETC and thereby increasing AMP, a mechanism that may be poorly suited for patients with mitochondrial disease stemming from primary ETC abnormalities. The gene discussed is PRKAA1; the disease is inborn mitochondrial metabolism disorder.